Viridian Therapeutics price target raised to $36 from $32 at Oppenheimer

Oppenheimer raised the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $32 and keeps an Outperform rating on the shares. The firm believes the recent royalty financing – which could well enable Viridian to achieve profitability without further equity dilution – sets a firm capital foundation as the company nears commercial entry into the $2B annual U.S. thyroid eye disease market. Oppenheimer sees shares continuing to run as what it expects to be a series of positive events transpires: IV veligrotug’s BLA submission in the coming weeks and subcutaneous VRDN-003’s Phase 3 readouts in the first half of 2026.